Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow PODD
Insulet Corporation (PODD) Price to free cash flow
As of 16 October 2026, Insulet Corporation (PODD) trades at a price to free cash flow of 36.8×. Over the past ten years it has ranged from 0.0× (December 2023) to 2,511× (December 2015); the current reading is higher than 77% of that period. That is above the Medical Devices industry median of 23.7× and above the Healthcare sector median of 20.2×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 57.1× | (7.48%) |
| FY2024 | 61.8× | (84.54%) |
| FY2023 | 400× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 39.7× | 4.90% |
| Mar 2026 | 37.9× | (33.73%) |
| Dec 2025 | 57.1× | 7.19% |
| Sep 2025 | 53.3× | (5.48%) |
| 42 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| GKOS Glaukos Corporation compare | n/m |
| SNN Smith & Nephew SNATS, Inc. compare | 6.4× |
| GMED Globus Medical, Inc. compare | 14.1× |
| HAE Haemonetics Corporation compare | 18.3× |
| BIO Bio-Rad Laboratories, Inc. compare | 26.6× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 27.4× |
| PODD Insulet Corporation | 36.8× |
| PEN Penumbra, Inc. compare | 58.5× |
| BRKR Bruker Corporation compare | 70.3× |
| Medical Devices industry median | 23.7× |
| Healthcare sector median | 20.2× |
| Market median | 14.2× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement